Biotech Values

[DewDiligence]

ABBV is not a stock I’d want for a large, long-term position. Although I expect ABBV to thrive in HCV during the next few years, I’m playing that angle via ENTA; further out, ABBV could be halved in a single day if the FDA were to approve an interchangeable generic Humira.

ABT, meanwhile, is the kind of boring stock that is almost guaranteed to underperform during a roaring bull market. However, baring some kind of global calamity, ABT can be counted on to produce slow and steady growth for many years to come.